James C. Clemmer
Net Worth

Last updated:

What is James C. Clemmer net worth?

The estimated net worth of Mr. James C. Clemmer is at least $21,291,553 as of 7 Oct 2024. He owns shares worth $6,011,553 as insider and has received compensation worth at least $15,280,000 in AngioDynamics, Inc..

What is the salary of James C. Clemmer?

Mr. James C. Clemmer salary is $1,910,000 per year as Chief Executive Officer, Pres & Director in AngioDynamics, Inc..

How old is James C. Clemmer?

Mr. James C. Clemmer is 61 years old, born in 1964.

What stocks does James C. Clemmer currently own?

As insider, Mr. James C. Clemmer owns shares in one company:

Company Title Shares Price per share Total value
AngioDynamics, Inc. (ANGO) Chief Executive Officer, Pres & Director 681,582 $8.82 $6,011,553

What does AngioDynamics, Inc. do?

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

ANGO logo
ANGO
AngioDynamics, Inc.
$8.82

James C. Clemmer insider trading

AngioDynamics, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 20,000 $6.03 $120,600
Option
Common Stock 56,279 N/A N/A
Option
Performance Right 52,378 N/A N/A
Purchase
Common Stock 10,000 $6.7 $67,000
Option
Performance Right 108,871 N/A N/A
Option
Common Stock 31,572 N/A N/A
Purchase
Common Stock 10,000 $15 $150,000
Option
Common Stock 25,123 N/A N/A
Option
Performance Right 50,139 N/A N/A
Purchase
Common Stock 10,000 $22.84 $228,400
Option
Performance Right 50,139 N/A N/A
Option
Common Stock 19,387 N/A N/A
Purchase
Common Stock 40,000 $8.26 $330,400
Purchase
Common Stock 15,000 $14.19 $212,850
Option
Performance Right 250,000 N/A N/A
Option
Common Stock 200,000 N/A N/A
Purchase
Common Stock 5,000 $15.79 $78,950
Purchase
Common Stock 20,000 $15.64 $312,800

AngioDynamics key executives

AngioDynamics, Inc. executives and other stock owners filed with the SEC:

  • Mr. Chad T. Campbell (54) Senior Vice President & GM of Vascular Access Global Bus. Unit
  • Mr. David D. Helsel (61) Senior Vice President of Global Operations and R&D
  • Mr. James C. Clemmer (61) Chief Executive Officer, Pres & Director
  • Mr. Stephen A. Trowbridge (51) Executive Vice President & Chief Financial Officer
  • Mr. Warren G. Nighan (56) Senior Vice President of Quality & Regulatory Affairs